Request Demo
Recent blog posts
Latest Hotspot
8 min read
Castration-resistant prostate cancer Indication Strategy Report 2026: PSMA, Trials and Deals
23 July 2026
2026 Castration-resistant prostate cancer strategy: epidemiology, PSMA biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Non-muscle-invasive bladder cancer Indication Strategy Report 2026: IL-15, Trials and Deals
23 July 2026
2026 Non-muscle-invasive bladder cancer strategy: epidemiology, IL-15 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Upper tract urothelial carcinoma Indication Strategy Report 2026: FGFR3, Trials and Deals
23 July 2026
2026 Upper tract urothelial carcinoma strategy: epidemiology, FGFR3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Small cell bladder cancer Indication Strategy Report 2026: DLL3, Trials and Deals
23 July 2026
2026 Small cell bladder cancer strategy: epidemiology, DLL3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
MET exon 14 skipping non-small cell lung cancer Indication Strategy Report 2026: c-Met, Trials and Deals
23 July 2026
2026 MET exon 14 skipping non-small cell lung cancer strategy: epidemiology, c-Met biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
RET fusion-positive non-small cell lung cancer Indication Strategy Report 2026: RET, Trials and Deals
23 July 2026
2026 RET fusion-positive non-small cell lung cancer strategy: epidemiology, RET biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
ALK-positive non-small cell lung cancer Indication Strategy Report 2026: ALK, Trials and Deals
23 July 2026
2026 ALK-positive non-small cell lung cancer strategy: epidemiology, ALK biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
KRAS G12C-mutant non-small cell lung cancer Indication Strategy Report 2026: KRAS G12C, Trials and Deals
23 July 2026
2026 KRAS G12C-mutant non-small cell lung cancer strategy: epidemiology, KRAS G12C biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Squamous non-small cell lung cancer Indication Strategy Report 2026: PD-1, Trials and Deals
23 July 2026
2026 Squamous non-small cell lung cancer strategy: epidemiology, PD-1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cutaneous squamous cell carcinoma Indication Strategy Report 2026: PD-1, Trials and Deals
23 July 2026
2026 Cutaneous squamous cell carcinoma strategy: epidemiology, PD-1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Basal cell carcinoma Indication Strategy Report 2026: SMO, Trials and Deals
23 July 2026
2026 Basal cell carcinoma strategy: epidemiology, SMO biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
6 min read
Romlusevimab Biologics Sequence Review Report 2026: SARS-CoV-2 Spike RBD Similarity and Patent-Risk Signals
23 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Romlusevimab, an antibody targeting SARS-CoV-2 Spike RBD.